Algernon Pharmaceuticals Inc.
AGN
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 255.50K | 441.80K | 446.80K | 56.20K | 54.60K |
| Total Receivables | 9.60K | 11.60K | 6.70K | 22.90K | 10.60K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 38.90K | 94.00K | 50.00K | 11.70K | 24.50K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 303.90K | 547.50K | 503.50K | 90.80K | 89.70K |
|
|
|||||
| Total Current Assets | 303.90K | 547.50K | 503.50K | 90.80K | 89.70K |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 2.28M | 2.35M | 2.33M | 2.80M | 2.80M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 20.50K | 21.30K | 21.10K | 21.20K | 21.20K |
| Total Assets | 2.61M | 2.92M | 2.85M | 2.91M | 2.91M |
|
|
|||||
| Total Accounts Payable | 1.31M | 1.30M | 1.29M | 2.34M | 2.11M |
| Total Accrued Expenses | 19.90K | 17.00K | 126.40K | 250.60K | 53.20K |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 1.33M | 1.32M | 1.42M | 2.59M | 2.17M |
|
|
|||||
| Total Current Liabilities | 1.33M | 1.32M | 1.42M | 2.59M | 2.17M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 1.33M | 1.32M | 1.42M | 2.59M | 2.17M |
|
|
|||||
| Common Stock & APIC | 21.10M | 21.90M | 21.36M | 21.45M | 20.74M |
| Retained Earnings | -22.20M | -22.79M | -22.31M | -23.49M | -23.07M |
| Treasury Stock & Other | 2.38M | 2.50M | 2.39M | 2.36M | 3.08M |
| Total Common Equity | 1.28M | 1.61M | 1.44M | 322.20K | 746.10K |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.28M | 1.61M | 1.44M | 322.20K | 746.10K |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.28M | 1.61M | 1.44M | 322.20K | 746.10K |
|
|
|||||